Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments196
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion57
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis46
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed41
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis39
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions34
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools31
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?31
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion31
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome30
Clinical pharmacology of antiplatelet drugs30
Reducing the risk of death – a possible outcome in COPD patients28
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?28
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis28
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review27
The pharmacotherapeutics of sarcoidosis26
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy26
Dostarlimab for the treatment of advanced endometrial cancer24
Amylin analogs for the treatment of obesity without diabetes: present and future23
Fetal safety of medications used in treating infertility23
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial21
0.30997109413147